Should I Buy LMND? LMND 2026 Analysis

Should You Buy Lemonade Inc (LMND) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

86.730

1 Day change

-4.98%

52 Week Range

99.900

Analysis Updated At

2026/01/30

LMND is not a good buy right now for an impatient investor. The primary trend is still bullish (moving averages stacked up), but momentum is cooling (MACD histogram contracting), the pattern-based short-term read favors a near-term dip, and insiders have been selling aggressively. With earnings coming up on 2026-02-19 (pre-market), the risk/reward for buying immediately is not compelling versus waiting for either a pullback toward support (~$88) or a fresh momentum trigger.

Technical Analysis

Trend: Bullish. The moving averages are strongly constructive (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend. Momentum: Positive but slowing. MACD histogram is above zero (0.778) but positively contracting, which often signals the uptrend is losing steam and may consolidate/pull back. RSI: Neutral-to-slightly-warm. RSI_6 at 60.74 suggests no extreme condition; not overbought, but not a clear “value entry” either. Levels: Pivot support is ~87.77 (key near-term line). Resistance levels are ~96.90 (R1) and ~102.54 (R2). At ~90.97, the stock is closer to support than resistance, but not at an obvious ‘must-buy’ level. Short-term statistical pattern read: Similar-pattern analysis implies a 70% chance of about -3.03% next day, +8.16% next week, and -4.53% next month—suggesting choppiness and elevated near-term timing risk. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Mildly bullish. Both open interest and volume put/call ratios are below 1 (0.62 and 0.63), indicating calls outweigh puts. Volatility: Elevated. 30D implied vol ~82% vs historical vol ~116%, implying rich option pricing but less extreme than realized; IV percentile ~44 and IV rank ~31 suggest it’s not at peak panic levels. Activity: Today’s option volume (11,452) is only ~55% of the 30-day average, so the bullish put/call read is not being reinforced by unusually heavy fresh flow.

Technical Summary

Sell

Buy

Positive Catalysts

Earnings catalyst ahead: Q4 2025 results on 2026-02-19 pre-market—can re-rate shares if loss ratios/cat losses come in better than feared.
Street narrative improving: Multiple firms have raised targets recently; focus is on pricing trends and improving loss ratio / path to EBITDA profitability by Q4
Options positioning leans bullish (put/call ratios < 1), consistent with constructive sentiment.

Neutral/Negative Catalysts

Insider selling is a major near-term negative: insider selling increased ~121% over the last month, which often caps upside in the short run.
Profitability still absent: the company remains unprofitable and is exposed to catastrophe-loss variability; any Q4 cat-loss surprise can hit the stock.
Industry cycle risk: commentary points to softness/transition in property lines; a softening P&C cycle into 2026 is a debated headwind.
Near-term timing risk: technical momentum is cooling and the pattern-based read favors a short-term dip.

Financial Performance

Latest quarter: 2025/Q3. Growth: Revenue grew strongly to $194.5M (+42.39% YoY), indicating solid top-line expansion. Profitability: Net income was -$37.5M (loss widened vs prior year: -44.61% YoY) and EPS was -$0.51 (down -46.32% YoY). The key takeaway is strong growth but worsening bottom-line performance, keeping the investment case dependent on future underwriting/scale improvements rather than current earnings strength.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets have generally moved up, reflecting improved confidence in the growth story and a clearer path toward EBITDA profitability. Key actions: - Truist initiated Buy with $98 PT (2026-01-06), emphasizing structural cost advantages from a digital/AI-first model. - Citizens raised PT to $85 and reiterated Outperform (2026-01-16). - Morgan Stanley upgraded to Equal Weight with $85 PT (2025-12-16), citing auto growth and loss ratio improvement; previously more bearish. - Keefe Bruyette remains Underperform with a much lower $40 PT (2025-11-25), highlighting continued skepticism on 2026 expectations. Wall Street pros: AI/digital advantage, strong growth (notably auto), improving loss ratios, path to EBITDA profitability. Wall Street cons: Still-lossmaking, catastrophe/insurance cycle risk, and a meaningful bear case remains (KBW Underperform). Influential/politician activity: No recent congress trading data available; no politician/influential buying/selling noted in the provided data.

6 Analyst Rating

Wall Street analysts forecast LMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMND is 77.6 USD with a low forecast of 40 USD and a high forecast of 98 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

1 Sell

Hold

Current: 91.280

Low

Averages

77.6

High

Current: 91.280

Low

Averages

77.6

High

Citizens

Outperform

maintain

$80 -> $85

AI Analysis

2026-01-16

Reason

Citizens

Price Target

$80 -> $85

AI Analysis

2026-01-16

maintain

Outperform

Reason

Citizens raised the firm's price target on Lemonade to $85 from $80 and keeps an Outperform rating on the shares. Fourth quarter results are expected to reflect lighter catastrophe losses and limited mark-to-market impacts, with attention focused on pricing trends amid weakness in property lines, the analyst tells investors in a research note. While property pricing is declining, returns remain strong and casualty lines continue to see solid rate increases, pointing to a market in transition rather than broadly soft, the firm says.

Truist

Arvind Ramnani

Buy

initiated

$98

2026-01-06

Reason

Truist

Arvind Ramnani

Price Target

$98

2026-01-06

initiated

Buy

Reason

Truist analyst Arvind Ramnani initiated coverage of Lemonade with a Buy rating and $98 price target. Lemonade's digital-first approach to the insurance industry provides the company with significant structural advantages such as a lower overall cost base relative to traditional insurers, the analyst tells investors in a research note. Lemonade leverages AI, data, and digital tools across entire business, including customer service, claims, processing, and underwriting decisions, which helps to reduce costs and biases, Truist says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LMND

Unlock Now

LMND Should I Buy

LMND Should I Buy

Should You Buy Lemonade Inc (LMND) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch